Cytokinetics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 55.8m | 70.4m | 94.6m | 7.5m | 13.5m | 77.1m | 360m |
| % growth | 108 % | 26 % | 34 % | (92 %) | 79 % | 471 % | 367 % |
| EBITDA | (88.6m) | (186m) | (313m) | (457m) | (527m) | (490m) | (309m) |
| % EBITDA margin | (159 %) | (264 %) | (331 %) | (6065 %) | (3905 %) | (635 %) | (86 %) |
| Profit | (127m) | (215m) | (389m) | (526m) | (565m) | (556m) | (401m) |
| % profit margin | (228 %) | (306 %) | (411 %) | (6989 %) | (4184 %) | (721 %) | (111 %) |
| EV / revenue | 20.5x | 49.6x | 44.0x | 1086.2x | 459.7x | 79.0x | 17.0x |
| EV / EBITDA | -12.9x | -18.8x | -13.3x | -17.9x | -11.8x | -12.4x | -19.8x |
| R&D budget | 97.0m | 160m | - | - | - | - | - |
| R&D % of revenue | 174 % | 227 % | - | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$40.0m | Series E | ||
| N/A | N/A | IPO | |
$33.0m | Post IPO Equity | ||
$20.0m | Post IPO Equity | ||
| N/A | $42.5m | Post IPO Equity | |
| N/A | $37.4m | Post IPO Equity | |
* | N/A | $201m | Post IPO Equity |
* | N/A | $316m | Post IPO Equity |
* | $450m | Post IPO Debt | |
* | N/A | $500m | Post IPO Equity |
| Total Funding | AUD92.7m | ||
Related Content
Recent News about Cytokinetics
EditCytokinetics, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines aimed at improving muscle function. The company primarily focuses on cardiovascular and neuromuscular diseases, which often lead to muscle weakness, fatigue, and impaired muscle function. These conditions include heart failure, hypertrophic cardiomyopathy (HCM), amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA).
Cytokinetics operates in the healthcare and pharmaceutical market, serving patients who suffer from these debilitating diseases. The company's clients include healthcare providers, hospitals, and patients who are in need of novel treatments to manage their conditions.
The business model of Cytokinetics revolves around the development and commercialization of small molecule muscle activators and inhibitors. These are specialized drugs designed to either enhance or inhibit muscle function, depending on the therapeutic need. The company has a robust pipeline of potential medicines, including omecamtiv mecarbil, reldesemtiv, CK-274, AMG 594, and CK-601. These drugs are currently in various stages of clinical trials, with the goal of bringing them to market to meet the unmet needs of patients.
Cytokinetics makes money through the successful development and commercialization of its drugs. Revenue streams include partnerships with other pharmaceutical companies, licensing agreements, and eventually, sales of approved medicines. The company has conducted over 50 clinical trials, demonstrating its commitment to rigorous scientific research and development.
In summary, Cytokinetics is a biopharmaceutical company focused on creating new treatments for cardiovascular and neuromuscular diseases. It serves healthcare providers and patients, operates in the healthcare market, and generates revenue through drug development and commercialization.
Keywords: biopharmaceutical, muscle function, cardiovascular, neuromuscular, heart failure, ALS, HCM, SMA, drug development, clinical trials.
